Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system

BACKGROUND: The buprenorphine transdermal system (BTDS) is approved in the US for the management of chronic pain. Due to its high affinity for μ-opioid receptors with a slow dissociation profile, buprenorphine may potentially displace or prevent the binding of competing μ-opioid-receptor agonists, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Silverman, Sanford, Raffa, Robert B, Cataldo, Marc J, Kwarcinski, Monica, Ripa, Steven R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449099/
https://www.ncbi.nlm.nih.gov/pubmed/28579823
http://dx.doi.org/10.2147/JPR.S132595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449099/
https://www.ncbi.nlm.nih.gov/pubmed/28579823
http://dx.doi.org/10.2147/JPR.S132595

Ejemplares similares